Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRONOMOS: rivaroxaban versus enoxaparin for venous thromboembolism prophylaxis after non-major lower-limb orthopaedic surgery
NL-OMON46019Phase 3Active, not recruiting
- Sponsor
- CHU Saint-Etienne
- Start
- Jan 2018
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in venous thromboembolism (VTE) comparing Rivaroxaban arm with Enoxaparin arm (2 arms). Primary endpoint: Major venous thromboembolic events. Started Jan 2018; status: active, not recruiting.
02
Drugs
rivaroxabanenoxaparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NL-OMON46019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46019.